Arabinogalactan: study protocols
10 study groups say how much Arabinogalactan participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from products
271 products in our catalogue print how much Arabinogalactan a serving holds.
Most common: 25 mg to 50 mg, 45% of 271 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 2 |
| 10 mg to 25 mg | 41 |
| 25 mg to 50 mg | 123 |
| 50 mg to 100 mg | 32 |
| 100 mg to 250 mg | 12 |
| 250 mg to 500 mg | 17 |
| 500 mg to 1 g | 13 |
| 1 g to 2.5 g | 24 |
| over 2.5 g | 7 |
Dose per serving from research
10 study groups in 6 studies say how much Arabinogalactan participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg and 2.5 g to 5 g and 10 g to 25 g, 20% of 10 study groups each.
| Daily dose | Study groups |
|---|---|
| 10 mg or less | 1 |
| 10 mg to 25 mg | 2 |
| 25 mg to 50 mg | 1 |
| 50 mg to 100 mg | 0 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 0 |
| 1 g to 2.5 g | 1 |
| 2.5 g to 5 g | 2 |
| 5 g to 10 g | 0 |
| 10 g to 25 g | 2 |
| over 25 g | 1 |
Commonly used together
4 of 10 study groups took Arabinogalactan with something else, but nothing that 3 or more different studies gave.
10 study groups
| Study | |||
|---|---|---|---|
| Difensil Immuno Reduces Recurrence and Severity of Tonsillitis in Children: A Randomized Controlled Trial 2020 · Group B (GB) · Children younger than 8 years with at least 3 fever-associated tonsillitis episodes per year and Mackenzie score >2 | 15 mg | 45 days | 41 |
| Difensil Immuno Reduces Recurrence and Severity of Tonsillitis in Children: A Randomized Controlled Trial 2020 · Group A (GA) · Children younger than 8 years with at least 3 fever-associated tonsillitis episodes per year and Mackenzie score >2 | 10 mg | 90 days | 40 |
| Immunomodulatory effects of ResistAid™: A randomized, double-blind, placebo-controlled, multidose study 2013 · 1.5 g/day of ResistAid · Healthy adults aged 18–60 years | 1.5 g | 60 days | 27 |
| Immunomodulatory effects of ResistAid™: A randomized, double-blind, placebo-controlled, multidose study 2013 · 4.5 g/day of ResistAid · Healthy adults aged 18–60 years | 4.5 g | 60 days | 25 |
| Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers 2010 · ResistAid™ (arabinogalactan) · Adults aged 18–65, male and female, described as healthy volunteers without major systemic, inflammatory, or chronic disease | 4.5 g | 72 days | 21 |
| Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects 2001 · 15 g arabinogalactan · Healthy adult men and women; ages not reported | 15 g | 3 weeks | — |
| Effects of dietary arabinogalactan on gastrointestinal and blood parameters in healthy human subjects 2001 · 30 g arabinogalactan · Healthy adult men and women; ages not reported | 30 g | 3 weeks | — |
| Effect of arabinogalactan on the gut microbiome: A randomized, double-blind, placebo-controlled, crossover trial in healthy adults 2021 · ResistAid · Healthy adults | 15 g | 6 weeks | — |
| Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study 2022 · TG1 · Hospitalized adults older than 65 years; sex not restricted; recruited for causes other than cancer, with specified immune-disease and infection exclusions | 15 mg | 12 weeks | 30 |
| Use of Nutraceuticals in Elderly to Fight Inflammation and Immuno-Senescence: A Randomized Case-Control Study 2022 · TG2 · Hospitalized adults older than 65 years; sex not restricted; recruited for causes other than cancer, with specified immune-disease and infection exclusions | 30 mg | 6 weeks | 30 |